Semaglutide

Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) used to treat type 2 diabetes by enhancing insulin secretion, reducing appetite, and promoting weight loss. It is administered as a subcutaneous injection once weekly and has shown significant efficacy in improving glycemic control and reducing body weight.

Semaglutide and Type 2 Diabetes: Efficacy, Safety, and Outcomes

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar through glucagon suppression.

Squid-inspired technology could replace needles for medications and vaccines

The MiDe systems, inspired by squid propulsion, demonstrate effective needle-free drug delivery in the gastrointestinal tract, rivaling traditional methods.

20 Nov 2024

More than half of all US adults are eligible for semaglutide therapy

Over 137 million US adults are eligible for semaglutide, driven by expanding indications for diabetes, weight management, and cardiovascular disease prevention.

20 Nov 2024

Diabetes drugs cut asthma attacks by up to 70%, reshaping treatment options

Metformin and GLP-1 receptor agonists significantly reduce asthma attacks in patients with type 2 diabetes, offering potential new treatments for asthma.

19 Nov 2024

Anti-obesity drugs show promise in improving cardiovascular health beyond weight loss

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers published in JACC, the flagship journal of the American College of Cardiology, that are being simultaneously presented at the American Heart Association's 2024 Scientific Sessions.

19 Nov 2024

Impact of glucagon-like peptide-1 receptor agonists on alcohol consumption

The impact of GLP-1 RAs on alcohol use is explored, showing potential benefits in reducing intake and cravings, but with mixed results from clinical trials.

19 Nov 2024

GLP-1 drugs, like semaglutide, lower risk of hospitalizations for alcohol use disorder

Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, warranting further clinical investigation.

18 Nov 2024

Intravenous infusion of exenatide fails to reduce risks of complications in heart surgery patients

A large-scale clinical trial found that intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) analog medication, during heart surgeries involving bypass did not significantly reduce the risk of death, stroke or organ failure.

18 Nov 2024

Tirzepatide improves heart health and function in obese HFpEF patients

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure events and cardiovascular death, and improved health status and physical function in comparison to participants taking placebo, according to late-breaking science presented today at the American Heart Association's Scientific Sessions 2024.

18 Nov 2024

Obesity crisis in the U.S. expected to worsen by 2050

Over the past three decades, there has been a startling increase in the prevalence of obesity across the USA, at least doubling in adult men and women (aged 25 and older) and older female and male adolescents (aged 15-24 years) since 1990, with the number of people living with overweight and obesity reaching over 208 million in 2021-;a trend set to continue in the coming decades without significant reform, according to a major new analysis from the Global Burden of Disease Study Collaborator Network, published in The Lancet.

15 Nov 2024

Diabetes medication shows promise in reducing alcohol use

New research, led by experts at the University of Nottingham, has found that certain types of medication used to treat diabetes may be effective in reducing alcohol use.

15 Nov 2024

Tirzepatide significantly reduces weight and diabetes risk in patients with obesity and prediabetes

Tirzepatide shows promise in reducing weight and preventing diabetes progression in people with obesity and prediabetes, with lasting benefits and manageable side effects.

14 Nov 2024

GLP-1 agonists linked to fewer hospitalizations in alcohol use disorder patients

A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, were associated with fewer hospitalizations among individuals with alcohol use disorder, AUD.

13 Nov 2024

Scientists discover new breakthrough in weight loss and diabetes treatment

Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or loss of muscle mass.

13 Nov 2024

GLP-1 and SGLT2 inhibitors show promise in preventing recurrent stroke and heart attack

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death in adults who had an initial stroke, according to a preliminary study to be presented at the American Heart Association's Scientific Sessions 2024.

11 Nov 2024

Weight loss drug semaglutide may offer relief for knee arthritis pain

Semaglutide shows promise in treating knee osteoarthritis by reducing pain and weight, offering a safe alternative to traditional pharmacological interventions.

4 Nov 2024

Semaglutide reduces urine albumin-to-creatinine ratio in overweight chronic kidney disease patients

Researchers investigate the clinical efficacy of semaglutide in controlling urine albumin-to-creatinine ratio in overweight patients with chronic kidney disease.

31 Oct 2024

New guidance balances GLP-1 risks and benefits for surgery

Most patients may continue to safely take glucagon-like peptide-1 (GLP-1) receptor agonists as prescribed before undergoing elective surgery and gastrointestinal endoscopies, according to new clinical guidance released today by five surgical and medical societies including the American Society for Metabolic and Bariatric Surgery (ASMBS), American Society of Anesthesiologists (ASA), American Gastroenterological Association (AGA), International Society of Perioperative Care of Patients with Obesity (ISPCOP), and Society of American Gastrointestinal and Endoscopic Surgeons (SAGES).

30 Oct 2024

Ozempic effective for patients with chronic kidney damage

In a 24-week trial, semaglutide led to a 52% reduction in albuminuria and improved kidney health in individuals with chronic kidney disease and obesity.

28 Oct 2024

Expanded access to weight-loss drugs could save thousands of lives

Researchers explore the potential benefits of expanding access to novel weight loss drugs to enhance survival rates in overweight and obese individuals.

28 Oct 2024

Study: GLP-1RA not associated with acute kidney injury risk during anti-cancer treatments

Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medications that are increasingly prescribed for patients with type 2 diabetes and congestive heart failure. Reports of GLP-1RA–associated acute kidney injury (AKI) have emerged, but the risk of GLP-1RA–associated AKI among patients on anti-cancer drugs is unclear.

26 Oct 2024

Semaglutide

Latest Semaglutide News and Research

Squid-inspired technology could replace needles for medications and vaccines

More than half of all US adults are eligible for semaglutide therapy

Diabetes drugs cut asthma attacks by up to 70%, reshaping treatment options

Anti-obesity drugs show promise in improving cardiovascular health beyond weight loss

Impact of glucagon-like peptide-1 receptor agonists on alcohol consumption

GLP-1 drugs, like semaglutide, lower risk of hospitalizations for alcohol use disorder

Intravenous infusion of exenatide fails to reduce risks of complications in heart surgery patients

Tirzepatide improves heart health and function in obese HFpEF patients

Obesity crisis in the U.S. expected to worsen by 2050

Diabetes medication shows promise in reducing alcohol use

Tirzepatide significantly reduces weight and diabetes risk in patients with obesity and prediabetes

GLP-1 agonists linked to fewer hospitalizations in alcohol use disorder patients

Scientists discover new breakthrough in weight loss and diabetes treatment

GLP-1 and SGLT2 inhibitors show promise in preventing recurrent stroke and heart attack

Weight loss drug semaglutide may offer relief for knee arthritis pain

Semaglutide reduces urine albumin-to-creatinine ratio in overweight chronic kidney disease patients

New guidance balances GLP-1 risks and benefits for surgery

Ozempic effective for patients with chronic kidney damage

Expanded access to weight-loss drugs could save thousands of lives

Study: GLP-1RA not associated with acute kidney injury risk during anti-cancer treatments

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Semaglutide

Latest Semaglutide News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in